Manufacturing news briefs – stories you might have missed

Cimic returns to growth after Covid disruption

Diversified engineering company Cimic Group has seen sales return to growth in the third quarter after the Covid-19 pandemic affected sales in early 2020. The engineering and mining services business reported revenue for the first nine months of the year of $9.3 billion, down from $10.7 billion, and net profit after tax of $474 million. Cimic controls a range of well known businesses such as UGL, Thiess, civil engineer CPB contractors, construction firm Leighton Asia and Sedgeman mineral processing equipment.

Optiscan in studies to tackle the US market

Medical imaging company Optiscan Imaging is to begin third party validation of its InVivage oral cancer screening system in preparation for an application for approval for sale in the United States. The system, based on microscopic imaging of affected areas, will undergo clinical trials at the Melbourne Dental School, while third party validation and testing proceeds. An application to the US Food and Drug Administration will follow.

Elsight gets new order for communications solution

Video and data cellular communication company Elsight has received a repeat order for its secure communications equipment from an international operator of cash transit transportation services. The order, worth $190,000 is to equip further armoured transport vehicles with its equipment.

Archer progresses patent protection

Materials technology company Archer Materials has progresses patent protection over two areas of its business. Patent application shave been filed and published in seven jurisdictions over its technologies relating to the design of a quantum computing qubit processor chip. A patent application over its graphene-based biosensor technology has been filed under the Patent Cooperation Treaty, which covers multiple markets.

Patrys granted patent over nanoparticle cancer treatment

Antibody therapy company Patrys has been granted a patent in Australia for the use of Deoxymab nanoparticles to deliver antibodies to cancer cells. The company is commercialising two nanoparticles that bind to DNA in solid cancer cells, targeting the delivery of anti-cancer drugs.

Picture: CIMIC Group/UGL

Subscribe to our free @AuManufacturing newsletter here.